OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
MWN-AI** Summary
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company specializing in innovative therapies for ocular conditions, announced its application for Fast Track designation from the U.S. Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101). Designed to treat neuropathic corneal pain, a debilitating condition characterized by chronic eye discomfort and currently lacking any FDA-approved treatment, this application represents a crucial step towards addressing the urgent needs of affected patients, estimated in the tens of thousands globally.
Gary S. Jacob, Ph.D., CEO of OKYO Pharma, emphasized the significance of this milestone, noting that the FDA's Fast Track designation aims to expedite the development and review of drugs that address serious conditions without existing approved therapies. This designation allows for enhanced communication with the FDA, quicker feedback on clinical trial designs and regulatory pathways, and the potential for a rolling review process.
Neuropathic corneal pain results from nerve damage and inflammation, leading to severe sensitivity in the eyes, face, or head. Current management typically involves off-label use of various treatments, underscoring the unmet medical need for an approved solution. Urcosimod, a lipid-conjugated chemerin peptide agonist designed to target the ChemR23 receptor, aims to provide anti-inflammatory and pain-reducing effects essential for treating this condition.
Following successful outcomes in a Phase 2 trial for dry eye disease, urcosimod is now undergoing a Phase 2 randomized, placebo-controlled trial specifically targeting neuropathic corneal pain. As OKYO Pharma continues its mission to develop novel therapies for these ocular conditions, the Fast Track designation could significantly accelerate the path toward bringing urcosimod to market. For more information, visit [OKYO Pharma's website](www.okyopharma.com).
MWN-AI** Analysis
In recent news, OKYO Pharma Limited (NASDAQ: OKYO) filed for Fast Track designation with the U.S. FDA for its investigational therapy, urcosimod, targeting neuropathic corneal pain (NCP). This condition, which can cause debilitating discomfort, currently has no FDA-approved treatment options, highlighting a significant market opportunity given the unmet medical need.
The Fast Track designation is pivotal for OKYO because it not only accelerates the development process but also facilitates closer communication with the FDA. By streamlining clinical trial designs and potentially enabling a rolling review process, the company could significantly shorten the time to market, especially for a drug addressing a serious condition like NCP. As neuropathic corneal pain affects thousands globally, the successful development and approval of urcosimod could position OKYO as a leader in a niche but lucrative segment of the ocular therapeutic market.
The company’s previous Phase 2 trials have demonstrated statistically significant efficacy in treating dry eye disease and are currently ongoing for NCP. This evidence strengthens the case for urcosimod as a transformative solution for those suffering from severe eye pain, offering potential to redefine current treatment paradigms.
Given the clinical progress and market dynamics, investors might find value in OKYO shares, driven by both the therapeutic potential of urcosimod and the favorable regulatory environment emerging from the Fast Track designation. However, as with any clinical-stage biotech, investment comes with inherent risks, especially around trial outcomes and regulatory approvals.
In conclusion, monitoring the progress of the Phase 2 trial results and FDA communications will be critical for stakeholders. Strategic positioning and robust data could yield significant upside, making OKYO an intriguing prospect in the biopharmaceutical landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease, a multi-billion-dollar market, is pleased to announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101) for the treatment of neuropathic corneal pain, which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort for which there is no FDA-approved, effective treatment.
“Fast track was first introduced by FDA to expedite development and review of drugs to treat serious conditions lacking any FDA-approved drug,” commented Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO Pharma. “Notably, neuropathic corneal pain falls into this category, and our application for Fast Track designation marks a significant milestone in our commitment to addressing the urgent needs of patients suffering from this type of pain. It is our belief that urcosimod has the potential to redefine the treatment paradigm for individuals grappling with this challenging condition.”
About FDA Fast Track Designation
At this stage of development, a drug that receives Fast Track designation is eligible for some or all of the following:
- More frequent meetings with FDA to discuss the drug’s development plan, ensure collection of appropriate data needed to support drug approval, plus the use of a rolling FDA review to expedite its regulatory path.
- Quicker turnaround on written communication from FDA regarding such things as the design of the proposed clinical trials and potential use of biomarkers.
For more information on fast track designation: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
About NCP
Neuropathic corneal pain is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of neuropathic corneal pain is unknown but is thought to result from nerve damage to the cornea combined with inflammation . Neuropathic corneal pain, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. Notably, there is no FDA approved drug to treat this debilitating condition.
About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial.
For further information, please visit www.okyopharma.com .
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
How do the regulatory environments of the LSE and NASDAQ impact OKYO Pharma's strategy for gaining Fast Track designation from the FDA for urcosimod?
What implications does OKYO Pharma's Fast Track application have on its stock performance on the NASDAQ compared to potential listings on the LSE?
In what ways does the lack of approved treatments in both the U.S. and U.K. markets, including the LSE, influence investor interest in OKYO Pharma's developments?
How might successful trials for urcosimod affect future partnerships or funding opportunities on both NASDAQ and LSE for OKYO Pharma?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
0.0% G/L:
$1.68 Last:
15,469 Volume:
$1.69 Open:
